| Foa, Edna B |
| Completed | 3 | 64 | US | Estradiol, Estrace, Placebo oral tablet, Prolonged Exposure (PE) therapy | The University of Texas Health Science Center, Houston, National Institute of Mental Health (NIMH) | PTSD | 05/24 | 12/24 | | |
| Recruiting | 1 | 80 | US | Estradiol, Estrace, Placebo | NYU Langone Health | Stress Disorders, Post-Traumatic, Healthy | 11/22 | 11/22 | | |
NCT05359562: How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD |
|
|
| Recruiting | N/A | 120 | US | Exposure & Response Prevention (EX/RP) | University of Pennsylvania, New York State Psychiatric Institute, New York University, Research Foundation for Mental Hygiene, Inc. / Columbia University, National Institute of Mental Health (NIMH) | OCD | 06/26 | 06/26 | | |
| Stadtmauer, Edward |
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration |
|
|
| Recruiting | 3 | 1100 | Canada, US | Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20 | SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP | Multiple Myeloma | 07/29 | 07/40 | | |
|
| Terminated | 1 | 16 | Europe, US | LAVA-051, Interleukin 2 | Lava Therapeutics, LAVA Therapeutics N.V., LAVA Therapeutics B.V. | Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia | 09/23 | 09/23 | | |
|
|
|
| Recruiting | 1 | 250 | Europe, Canada, US, RoW | ADP adoptive cell therapy | Adaptimmune | Neoplasms | 04/32 | 04/32 | | |
NCT05448196: Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma |
|
|
| Completed | N/A | 103 | US | Coordinated Financial Navigation Program | Abramson Cancer Center at Penn Medicine | Multiple Myeloma | 06/23 | 06/23 | | |
| Soulen, Michael C |
NCT02764801: Contrast-enhanced Ultrasound Evaluation of Chemoembolization |
|
|
| Completed | 3 | 131 | US | Ultrasound contrast agent (Contrast-enhanced ultrasound), Definity (Lantheus Medical Imaging), Microbubble contrast agent, Logiq E9 Scanner (Contrast-enhanced ultrasound), Ultrasound Scanner | Sidney Kimmel Cancer Center at Thomas Jefferson University, University of California, San Diego, Vanderbilt University Medical Center, National Institutes of Health (NIH), Lantheus Medical Imaging, GE Healthcare, National Cancer Institute (NCI) | Hepatocellular Carcinoma, Chemoembolization, Therapeutic | 12/21 | 02/23 | | |
NCT05470205: Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal |
|
|
| Recruiting | 3 | 660 | Europe, US | SHAPE measurement (Sonazoid ultrasoud contrast agent), Sonazoid, SHAPE measurement (Definity ultrasoud contrast agent), Definity | Thomas Jefferson University, University of Pennsylvania, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Bern | Liver Diseases, Portal Hypertension | 02/26 | 04/26 | | |
NCT02724540: Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver |
|
|
| Completed | 2 | 162 | Europe, Canada, US, RoW | Bland Embolization, BE, Transarterial chemoembolization, TACE, Drug Eluting Beads Embolization, DEB | Abramson Cancer Center at Penn Medicine, Guerbet | Neuroendocrine Tumor, Malignant, Liver Metastases | 04/24 | 11/24 | | |
| Recruiting | 2 | 55 | US | Capecitabine tablets + temozolomide tablets + SIR-Spheres, SIR-Spheres | Abramson Cancer Center of the University of Pennsylvania, Roswell Park Cancer Institute, CARTI | Neuroendocrine Tumor Grade 2, Liver Metastases | 12/24 | 12/25 | | |
| Recruiting | 2 | 50 | US | Capecitabine Oral Product, Xeloda, Temozolomide Oral Product, Temodar, transarterial radioembolization, TARE, y90 | Abramson Cancer Center at Penn Medicine, Roswell Park Cancer Institute, University of California, San Diego, University of Miami Sylvester Comprehensive Cancer Center | Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors | 05/25 | 05/26 | | |
NCT02174549: Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer |
|
|
| Recruiting | 1/2 | 25 | US | Tirapazamine, Conventional Transarterial Embolization (TAE), TAE conducted with Lipiodol and Surgifoam as the embolizing agents. | Teclison Ltd. | Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors | 12/25 | 12/25 | | |
NCT04429321: Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary |
|
|
| Terminated | 1 | 1 | US | Nivolumab, Opdivo, Ipilimumab, Yervoy, bland embolization, trans-arterial embolization | Abramson Cancer Center at Penn Medicine | Renal Cell Carcinoma, Renal Cell Carcinoma Stage IV | 01/24 | 01/24 | | |
| Terminated | 1 | 5 | US | Axitinib 5 MG, Hydroxychloroquine Pill, trans arterial chemoembolization | Abramson Cancer Center at Penn Medicine, Pfizer | Colorectal Neoplasms Malignant | 04/24 | 04/24 | | |
| Recruiting | N/A | 12 | US | TACE Catheters | Abramson Cancer Center at Penn Medicine, TriSalus Life Sciences | Hepatocellular Carcinoma, Neuroendocrine Tumors | 01/26 | 06/26 | | |
DOORwaY90, NCT04736121: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients |
|
|
| Active, not recruiting | N/A | 100 | US | Resin microspheres containing yttrium-90 (Y-90) | Sirtex Medical, Bright Research Partners | Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | 10/25 | 12/26 | | |
| Recruiting | N/A | 70 | US | Quality of Life surveys, Abdominal CT | Abramson Cancer Center at Penn Medicine | Ascites Hepatic, Ascites, Malignant | 04/25 | 10/25 | | |
| Volpp, Kevin G |
ALLSTAR, NCT05176756: RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors |
|
|
| Active, not recruiting | N/A | 150 | US | Gamification and Social Support, Attention control | Abramson Cancer Center at Penn Medicine, American Heart Association, City of Hope National Medical Center | Cardiovascular Diseases, Breast Cancer, Prostate Cancer, Physical Inactivity | 11/24 | 03/25 | | |
| Active, not recruiting | N/A | 214 | US | Storefront Choice Architecture, Fresh Funds, Loss Framing | University of Pennsylvania | Obesity, Diabetes | 06/25 | 06/25 | | |
NCT04798664: Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening |
|
|
| Active, not recruiting | N/A | 3228 | US | Removal of Financial Barriers, Financial Incentives, Mobile Health Application | Abramson Cancer Center at Penn Medicine, Patient-Centered Outcomes Research Institute | Smoking Cessation | 11/24 | 07/25 | | |
| Recruiting | N/A | 1980 | US | Penn Med Healthy Heart Program, PMHH, HDPP | University of Pennsylvania | Hypertension, Hyperlipidemias | 03/25 | 06/25 | | |
| Wadden, Thomas A |
NCT04994769: The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT) |
|
|
| Completed | N/A | 33 | US | Epitomee Capsule, The MODEL IBT Program | Epitomee medical | Overweight and Obesity | 12/23 | 03/24 | | |
| Falk, Gary W |
| Active, not recruiting | 2 | 41 | US | Dupilumab (blinded), Placebo (blinded), Dupilumab (open-label) | Children's Hospital Medical Center, Cincinnati, Regeneron Pharmaceuticals, National Institutes of Health (NIH) | Eosinophilic Gastritis, Eosinophilic Gastroenteritis | 03/24 | 11/24 | | |
SURVENT, NCT05753748: Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia |
|
|
| Recruiting | N/A | 680 | US | Endoscopic Eradication Therapy | University of Colorado, Denver, Baylor University, University of North Carolina, Medical University of South Carolina, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma | 02/28 | 02/28 | | |
FBE, NCT00288119: Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma |
|
|
| Recruiting | N/A | 2000 | US | Balloon Capsule Device, Esophageal Sampling Device BESD-001, Endoscopy, EGD | Case Western Reserve University, University Hospitals Cleveland Medical Center, Washington University School of Medicine, Fred Hutchinson Cancer Center, University of Washington, Mercy Medical Center, Johns Hopkins University, Mayo Clinic, University of North Carolina, Chapel Hill, The Cleveland Clinic, University of Pennsylvania, Columbia University, VA Puget Sound Health Care System | Barrett's Esophagus, Esophageal Neoplasm | 07/28 | 07/28 | | |
NCT02523118: OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages |
|
|
| Recruiting | N/A | 1350 | US | | Children's Hospital Medical Center, Cincinnati, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), ORDR, National Center for Advancing Translational Sciences (NCATS) | Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis | 12/50 | 01/51 | | |
| Schuster, Stephen J |
UPCC 02408, NCT00783367: Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas |
|
|
| Completed | 2 | 50 | US | Lenalidomide, Revlimid (lenalidomide), Dexamethasone, Decadron (dexamethasone), Rituximab, Rituxan (rituximab) | Abramson Cancer Center at Penn Medicine | Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma | 11/12 | 11/20 | | |
|
NCT04305444: Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas |
|
|
| Terminated | 2 | 55 | US | DTRM-555, DTRMWXHS-12, everolimus, pomalidomide | Zhejiang DTRM Biopharma | Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's Transformation | 12/24 | 12/24 | | |
| Recruiting | 2 | 42 | US | mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101 | Abramson Cancer Center at Penn Medicine, Genentech, Inc. | Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma | 12/24 | 12/25 | | |
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) |
|
|
| Recruiting | 1/2 | 320 | Canada, US | JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax | Juno Therapeutics, a Subsidiary of Celgene | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic | 11/27 | 11/27 | | |
|
|
|
|
|
| Not yet recruiting | 1 | 12 | US | CD19 redirected autologous T cells (CTL019 or CTL119 cells) | University of Pennsylvania | Lymphoma, B-Cell | 07/27 | 07/27 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
| Nelson, Charles A |
| Active, not recruiting | 4 | 404 | US | Dexamethasone 4mg, Group 1, Dexamethasone 8 Mg/mL Injectable Suspension, Group 2, Dexamethasone 16mg, Group 3 | Rush University Medical Center | Total Knee Arthroplasty | 01/25 | 02/25 | | |
PEPPER, NCT02810704: Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement |
|
|
| Recruiting | 4 | 20000 | Canada, US | Enteric Coated Aspirin, Aspirin, Warfarin, Coumadin, Rivaroxaban, Xarelto | Dartmouth-Hitchcock Medical Center, Patient-Centered Outcomes Research Institute, University of Maryland, Baltimore, Brigham and Women's Hospital, Northwestern University, Medical University of South Carolina | Pulmonary Embolism, Venous Thrombosis | 07/25 | 07/25 | | |
NCT04713150: HEALthy Brain and Child Development Study - COVID-19 Supplement |
|
|
| Active, not recruiting | N/A | 75 | US | No Intervention | Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital | Child Development, Prenatal Infection, Prenatal Stress, Covid19 | 09/23 | 11/23 | | |
NCT05629624: Evaluation of Executive Function and Emotional Regulation in Children in Bangladesh |
|
|
| Recruiting | N/A | 280 | RoW | Chickpea based RUSF, E-RUSF, Outcome reference group/RUSF | Boston Children's Hospital, The University of The West Indies, International Centre for Diarrhoeal Disease Research, Bangladesh, University of Auckland, New Zealand, Wellcome Trust | Executive Function Disorder, Emotional Regulation, Malnutrition, Child | 08/24 | 08/24 | | |
NCT03737149: A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform |
|
|
| Active, not recruiting | N/A | 10500 | Europe, US, RoW | mymobility with Apple Watch | Zimmer Biomet | Osteoarthritis, Knee, Osteoarthritis, Hip | 12/24 | 07/25 | | |
| Active, not recruiting | N/A | 136 | Europe | Foster Care Placement, Foster Care Group | Charles Alexander Nelson III, Tulane University Health Sciences Center, University of Maryland, University of Minnesota, Temple University, Duke University, MacArthur Foundation, National Institute of Mental Health (NIMH), Vanderbilt University, Harvard University, University of North Carolina, Chapel Hill, University of Toronto | Cognitive Ability, General, Psychiatric and/or Mood Disorders, Brain Function, Social Cognition, Health Behavior, Risk-Taking, Executive Function | 03/25 | 03/25 | | |
NCT04165746: Early Institutionalization Intervention Impact Project |
|
|
| Recruiting | N/A | 220 | RoW | Foster Care, Caregiving Intervention, Attachment Video Feedback intervention | Boston Children's Hospital, University of Maryland, College Park, Tulane University, Instituto PENSI, Harvard University, Inter-American Development Bank, Lumos Foundation, Two Lilies Fund, Fundaçao Maria Cecilia Souto Vidigal | Socioemotional Development, Cognitive Ability, Behavioral and Neural Patterns of Attention, Brain Function, Psychopathology | 03/26 | 03/26 | | |
| Not yet recruiting | N/A | 192 | US | Core Decompression, Core Decompression Procedure with Autologous Bone Marrow Aspirate Concentrate | Johns Hopkins University, Stanford University, Sinai Hospital of Baltimore, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Osteonecrosis of the Femoral Head, Avascular Necrosis of the Femoral Head | 04/28 | 08/28 | | |
| Rickels, Michael |
| Active, not recruiting | 2 | 140 | Europe, US, RoW | Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo | Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a. | Recent Onset type1 Diabetes | 04/24 | 04/26 | | |
NCT04731272: GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance |
|
|
| Recruiting | 2 | 30 | US | Dulaglutide 0.75Mg/0.5Ml Inj Pen | University of Pennsylvania, Children's Hospital of Philadelphia | Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes | 06/26 | 06/27 | | |
| Active, not recruiting | 1 | 11 | US | Phentolamine, Regitine, Propranolol, Inderal, Placebo, Saline, Sodium Chloride Solution | University of Pennsylvania, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation | 04/19 | 12/24 | | |
NCT01474889: Glucose Counterregulation in Long Standing Type 1 Diabetes |
|
|
| Completed | N/A | 37 | US | RT-CGM, DexCom SEVEN PLUS, Guardian R-T, or FreeStyle Navigator. | University of Pennsylvania, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Hypoglycemia Unawareness, Type 1 Diabetes, Healthy | 05/16 | 03/21 | | |
| Completed | N/A | 10 | US | MiniMed 670G system | University of Pennsylvania, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type1diabetes, Hypoglycemia Unawareness, Nocturnal Hypoglycemia, Hypoglycemia Night, Hypoglycemia | 05/22 | 10/24 | | |
NCT01851694: Beta-cell Response to Incretin Hormones in Cystic Fibrosis |
|
|
| Recruiting | N/A | 45 | US | GLP-1, GIP, Glucose-dependent insulinotrophic polypeptide | University of Pennsylvania, Children's Hospital of Philadelphia | Cystic Fibrosis, Pancreatic Insufficiency | 12/25 | 12/25 | | |
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes |
|
|
| Completed | N/A | 319 | Canada, US | t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM) | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type 2 Diabetes Treated With Insulin | 09/24 | 09/24 | | |
| Not yet recruiting | N/A | 324 | Europe, US, RoW | Omnipod 5 or Medtronic 780G, My HypoCOMPaSS Education, HARPdoc Education | Milton S. Hershey Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Minnesota, University of Kentucky, University of Pennsylvania, AdventHealth, University of Leicester, University of Sheffield, University of Melbourne, Jaeb Center for Health Research, University of California, San Diego | Diabetes Mellitus, Type 1 | 06/27 | 12/27 | | |
NCT01852448: Genetics of Insulin and Incretins in Cystic Fibrosis |
|
|
| Recruiting | N/A | 550 | US | Blood or Saliva Sample Collection | Children's Hospital of Philadelphia, University of Pennsylvania | Cystic Fibrosis | 07/25 | 07/25 | | |
| Lee, Daniel |
| Recruiting | 3 | 640 | Europe, Canada, US | Low Energy SLT, Standard Energy SLT | West Virginia University, University of Pittsburgh | Glaucoma and Ocular Hypertension | 06/27 | 08/27 | | |
NCT05691465: Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells |
|
|
| Recruiting | 2 | 30 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Gallium Ga 68-DOTATATE, (68)Ga-DOTA-TATE, 68Ga-DOTA-0-Tyr3-Octreotate, 68Ga-DOTATATE, Gallium Ga 68 Oxodotreotide, Gallium Oxodotreotide Ga-68, Gallium-68 DOTA-DPhe1, Tyr3-octreotate, Lutetium Lu 177 Dotatate, 177 Lu-DOTA-TATE, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate, Lutathera, Lutetium (177Lu) Oxodotreotide, Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate, Lutetium Lu 177-DOTA-Tyr3-Octreotate, lutetium Lu 177-DOTATATE, Lutetium Oxodotreotide Lu-177, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT | National Cancer Institute (NCI) | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8 | 11/25 | 11/25 | | |
| Not yet recruiting | 2 | 136 | US | Enhanced Crisis Response Planning (ECRP), Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT) | VA Office of Research and Development | Suicide | 12/27 | 12/27 | | |
NCT03584958: Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries |
|
|
| Enrolling by invitation | N/A | 150 | US | | Wills Eye, Allergan, The American Society of Cataract and Refractive Surgery Foundation | Glaucoma, Ocular Hypertension | 12/22 | 06/23 | | |
NCT04784234: Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin |
|
|
| Recruiting | N/A | 100 | US | GlaucoCetin, Placebo | Wills Eye, Guardian Health Sciences, Inc. | Primary Open Angle Glaucoma | 02/23 | 12/23 | | |
NCT04396808: Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer |
|
|
| Recruiting | N/A | 900 | US | Decipher, Decipher Prostate Cancer Classifier, Prolaris, Prolaris Prostate Cancer Test, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score), askMUSIC score | University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), Myrexis Inc., Veracyte, Inc., MDx Health | Prostate Cancer | 07/25 | 07/25 | | |
| Active, not recruiting | N/A | 1720 | Europe, Canada, US | Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent) | Shanghai MicroPort Medical (Group) Co., Ltd. | Coronary Artery Disease | 12/23 | 06/27 | | |
NCT05325996: Evaluating Home Testing Devices for the Management of Glaucoma |
|
|
| Recruiting | N/A | 50 | US | Standard Automatic Perimetry Humphrey Field Analyzer, SAP HFA, visuALL H, iCare Home Tonometer, Spectralis Optical coherence tomography (OCT) | Wills Eye | Glaucoma, Open-Angle | 12/26 | 12/26 | | |
| Active, not recruiting | N/A | 80 | US | Syn-One Test | CND Life Sciences | REM Sleep Behavior Disorder (iRBD) | 12/25 | 12/25 | | |
| Recruiting | N/A | 3062 | US | CPAP | University of Michigan, National Institute of Neurological Disorders and Stroke (NINDS), FusionHealth LLC, Medical University of South Carolina, University of Cincinnati | Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial | 11/26 | 11/26 | | |
| Strasser, Andrew |
NCT05076708: The Effects of IQOS Use on Cigarette Smoking Behaviors |
|
|
| Completed | 1 | 102 | US | IQOS | University of Pennsylvania | Smoking, Cigarette Smoking, Tobacco Use | 02/24 | 05/24 | | |
NCT04906148: Young Adults' Reactions to Low Nicotine Cigarette Advertising |
|
|
| Completed | N/A | 56 | US | Advertisement content (explicit vs. implicit), Advertisement content (true vs. misleading) | Abramson Cancer Center at Penn Medicine, National Cancer Institute (NCI) | Smoking | 06/23 | 08/23 | | |
NCT05108649: Impact of Nicotine Messaging on Beliefs and Behavior |
|
|
| Completed | N/A | 74 | US | Nicotine Messaging, Cigarette Condition | Andrew Strasser, Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA), Rutgers University | Smoking Behaviors, Cigarette Smoking | 06/24 | 06/24 | | |
| Recruiting | N/A | 575 | US | LNC Cigarettes + Colored Packaging, Own Brand | Abramson Cancer Center at Penn Medicine, Food and Drug Administration (FDA), National Cancer Institute (NCI), University of Pennsylvania | Smoking, Cigarette | 09/25 | 09/25 | | |
| Wehrli, Felix W |
AeCE, NCT05271578: MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers |
|
|
| Recruiting | N/A | 40 | US | Standardized Electronic Research Cigarette, SREC, Nicotine Research Cigarette, NRC | University of Pennsylvania, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) | Vascular Reactivity, Serum Biomarkers | 08/25 | 08/25 | | |
| Milad, Mohammed R |
NCT05391971: Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder |
|
|
| Recruiting | 4 | 127 | US | Bupivacaine, Marcaine, Saline | NYU Langone Health | Post Traumatic Stress Disorder | 06/25 | 08/25 | | |
| Completed | 3 | 64 | US | Estradiol, Estrace, Placebo oral tablet, Prolonged Exposure (PE) therapy | The University of Texas Health Science Center, Houston, National Institute of Mental Health (NIMH) | PTSD | 05/24 | 12/24 | | |
NCT06240052: Use Electroencephalogram to Study Neural Dynamics of Fear Conditioning and Avoidance Learning Circuit in Humans |
|
|
| Recruiting | N/A | 150 | US | Conditioning and active avoidance paradigm (CAAP) | The University of Texas Health Science Center, Houston | Neural Dynamics of the Acquisition and Retention of Fear Learning and Active Avoidance Learning | 11/25 | 01/26 | | |
| Recruiting | N/A | 300 | US | Fear Conditioning, Avoidance conditioning, Pavlovian fear extinction learning, Willingness to pay to avoid shock | The University of Texas Health Science Center, Houston, National Institute of Mental Health (NIMH) | Post Traumatic Stress Disorder | 01/27 | 01/27 | | |
| Recruiting | N/A | 150 | US | Mindfulness Based Stress Reduction MBSR Intervention, Stress Education Control Condition (SE) | NYU Langone Health | Generalized Anxiety Disorder | 03/26 | 06/26 | | |
NCT05368987: Neuromodulation of the Fear Extinction Circuit Using Temporally and Anatomically Specific TMS in Humans |
|
|
| Recruiting | N/A | 250 | US | Transcranial magnetic stimulation (TMS), Fear Conditioning and Extinction Paradigm | The University of Texas Health Science Center, Houston, National Institute of Mental Health (NIMH) | PTSD | 09/27 | 09/27 | | |
| Reese, Peter P |
| Active, not recruiting | 2 | 201 | US | Epclusa | University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | End Stage Renal Disease | 06/25 | 01/26 | | |
| Completed | 1/2 | 10 | US | Zepatier, Epclusa | University of Pennsylvania, Merck Sharp & Dohme LLC | Lung Diseases | 12/21 | 12/22 | | |
| Completed | 1/2 | 62 | US | Zepatier, Mavyret | University of Pennsylvania, Merck Sharp & Dohme LLC | End Stage Renal Disease | 03/22 | 12/22 | | |
TEST, NCT05260268: Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant |
|
|
| Recruiting | N/A | 360 | US | TEST Intervention | University of Pennsylvania, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence | 07/26 | 01/27 | | |
| Svoboda, Jakub |
NCT03712202: Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma |
|
|
| Active, not recruiting | 2 | 155 | US | Bleomycin, BLEO, BLM, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Vinblastine, Vincaleucoblastine, VLB | City of Hope Medical Center, National Cancer Institute (NCI) | Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL | 12/24 | 12/24 | | |
| Recruiting | 2 | 42 | US | mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101 | Abramson Cancer Center at Penn Medicine, Genentech, Inc. | Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma | 12/24 | 12/25 | | |
NCT04659044: Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
|
|
| Terminated | 2 | 3 | US | Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | Academic and Community Cancer Research United, National Cancer Institute (NCI) | Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma | 03/24 | 03/24 | | |
| Completed | 1/2 | 8 | US | Lenalidomide, Revlimid, CC-5013 | Abramson Cancer Center of the University of Pennsylvania | Lymphoma | 05/18 | 10/22 | | |
| Active, not recruiting | 1/2 | 23 | US | Itacitinib, INCB039110, Everolimus, Afinitor | University of Pennsylvania | Classical Hodgkin Lymphoma | 05/24 | 06/27 | | |
| Recruiting | 1 | 24 | US | TmCD19-IL18 | University of Pennsylvania, Kite, A Gilead Company | Non Hodgkin Lymphoma | 10/26 | 10/41 | | |
| Recruiting | 1 | 72 | US | huCART19-IL18 | University of Pennsylvania | Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 05/36 | 05/36 | | |
| Terminated | N/A | 465 | US | clonoSEQ Assay | Adaptive Biotechnologies | Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma | 10/23 | 10/23 | | |
| Cohen, Sarah |
| Recruiting | 4 | 20000 | US | Atorvastatin 40 Mg Oral Tablet, Lipitor, Placebo oral tablet | Duke University, National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences | Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases | 12/26 | 12/26 | | |
| Completed | 2 | 145 | US | Pomalidomide Oral Product, POMALYST, Placebo oral capsule | The Cleveland Clinic, RTI International | Telangiectasia, Hereditary Hemorrhagic | 09/23 | 09/23 | | |
CARBON, NCT04035434: A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies |
|
|
| Terminated | 1/2 | 62 | Europe, Canada, US, RoW | CTX110 | CRISPR Therapeutics AG | B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL | 10/24 | 10/24 | | |
CRSP-ONC-006, NCT05643742: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies |
|
|
| Recruiting | 1/2 | 120 | US, RoW | CTX112 | CRISPR Therapeutics AG | B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma | 01/30 | 02/30 | | |
NCT04244656: A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Terminated | 1 | 26 | Europe, Canada, US, RoW | CTX120 | CRISPR Therapeutics AG | Multiple Myeloma | 01/24 | 01/24 | | |
|
| Libman, Ingrid |
| Active, not recruiting | 2 | 140 | Europe, US, RoW | Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo | Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a. | Recent Onset type1 Diabetes | 04/24 | 04/26 | | |
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) |
|
|
| Recruiting | 2 | 78 | US | Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer | Diabetes Mellitus, Type 1 | 06/26 | 06/27 | | |
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes |
|
|
| Recruiting | 2 | 74 | US, RoW | Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) | Type 1 Diabetes Mellitus | 10/27 | 10/29 | | |
| Active, not recruiting | 2 | 101 | US, RoW | Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 1 | 12/28 | 12/29 | | |
| Recruiting | N/A | 80 | US | DVx-T1D™ app | Carnegie Mellon University, University of Pittsburgh | Diabetes Mellitus, Type 1, Behavior, Health | 12/24 | 06/25 | | |
TREAT-ED, NCT06626347: Telemedicine for Reach, Education, Access, and Treatment for Diabetes Self-Management Education and Support |
|
|
| Enrolling by invitation | N/A | 48 | US | TREAT-ED Virtual Group Diabetes Self-Management Education and Support | University of Pittsburgh, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes (T1D) | 12/25 | 05/26 | | |
| Basner, Mathias |
| Active, not recruiting | N/A | 401 | US | | University of Pennsylvania, Federal Aviation Administration Office of Environment and Energy, Harris Miller Miller & Hanson Inc., Westat | Noise Exposure | 10/23 | 03/26 | | |
| Active, not recruiting | N/A | 24 | US | Aviation Noise Only (AN), Pink noise, 50 dBA only (BN50), Aviation noise plus earplugs (AN+EP), Aviation noise plus white noise 40 dBA (AN+BN40), Aviation noise plus white noise 50 dBA (AN+BN50), Control Night (CTRL) | University of Pennsylvania, Civil Aerospace Medical Institute | Noise Exposure | 06/24 | 12/24 | | |
| Nam, Denis |
NCT05113901: Medrol Dosepak Taper for Delayed Post-op Recovery After TKA |
|
|
| Terminated | 4 | 4 | US | Methylprednisolone, Placebo | Rush University Medical Center | Total Knee Arthroplasty | 07/22 | 07/22 | | |
| Active, not recruiting | 4 | 404 | US | Dexamethasone 4mg, Group 1, Dexamethasone 8 Mg/mL Injectable Suspension, Group 2, Dexamethasone 16mg, Group 3 | Rush University Medical Center | Total Knee Arthroplasty | 01/25 | 02/25 | | |
NCT03321799: Comparison of Negative Pressure Wound Therapy vs. Conventional Dressings for Prevention of Wound Complications After Revision THA |
|
|
| Active, not recruiting | 1 | 201 | US | Negative Pressure Wound Therapy (NPWT), Sterile Antimicrobial Dressings | Rush University Medical Center, 3M | Infection, Drainage | 03/24 | 01/25 | | |
| Leone, Frank T |
NCT04738643: Improving Tobacco Treatment Rates for Cancer Patients Who Smoke |
|
|
| Completed | N/A | 685 | US | Tobacco Use Treatment Service and Varenicline Management, TUTS + VM, TUT Service + VM | Abramson Cancer Center at Penn Medicine, University of Pennsylvania | Cancer, Tobacco Use, Smoking, Nicotine Dependence | 12/23 | 01/24 | | |
